Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumors (MK-8353-014)

Phase 1 Completed 30 enrolled Merck Sharp & Dohme LLC

NaSequentialOpen-labelTreatment

Summary

This is a multicenter, worldwide, open-label study of MK-8353 in combination with selumetinib in participants with histologically or cytologically confirmed diagnosis of advanced solid tumor. This study will evaluate the safety, tolerability, and exploratory efficacy of MK-8353 in combination with selumetinib.

Timeline

Start: 2019-02-22
Primary completion: 2021-03-19
Completion: 2021-03-19

Publications

Results Stathis A, Tolcher AW, Wang JS, Renouf DJ, Chen LC, Suttner LH, Freshwater T, Webber AL, Nayak T, Siu LL. Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors. Invest New Drugs. 2023 Jun;41(3):380-390. doi: 10.1007/s10637-022-01326-3. Epub 2023 Apr 11.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MK-8353	Small molecule	50 mg	Oral
Subject	MK-8353	Small molecule	100 mg	Oral
Subject	MK-8353	Small molecule	150 mg	Oral
Subject	MK-8353	Small molecule	200 mg	Oral
Subject	MK-8353	Small molecule	250 mg	Oral
Subject	Selumetinib	Small molecule	25 mg	Oral
Subject	Selumetinib	Small molecule	50 mg	Oral
Subject	Selumetinib	Small molecule	75 mg	Oral
Subject	Selumetinib	Small molecule	100 mg	Oral

Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumors (MK-8353-014)

Summary

Timeline

Publications

Drugs

Indications